iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Down 61.4% in April

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the recipient of a significant decrease in short interest in April. As of April 30th, there was short interest totaling 47,511 shares, a decrease of 61.4% from the April 15th total of 123,125 shares. Approximately 0.9% of the company’s stock are sold short. Based on an average daily volume of 55,288 shares, the short-interest ratio is currently 0.9 days.

iShares Genomics Immunology and Healthcare ETF Price Performance

NYSEARCA:IDNA traded down $0.73 during trading hours on Friday, reaching $28.81. The company’s stock had a trading volume of 26,040 shares, compared to its average volume of 42,070. The company has a market cap of $157.01 million, a price-to-earnings ratio of 14.76 and a beta of 0.97. iShares Genomics Immunology and Healthcare ETF has a one year low of $19.59 and a one year high of $31.41. The business’s 50-day moving average is $29.53 and its 200-day moving average is $28.23.

Institutional Investors Weigh In On iShares Genomics Immunology and Healthcare ETF

Large investors have recently bought and sold shares of the business. Triumph Capital Management bought a new stake in iShares Genomics Immunology and Healthcare ETF in the third quarter worth $35,000. Ameriprise Financial Inc. boosted its holdings in iShares Genomics Immunology and Healthcare ETF by 8.4% in the third quarter. Ameriprise Financial Inc. now owns 71,473 shares of the company’s stock worth $1,688,000 after purchasing an additional 5,540 shares in the last quarter. Finally, Portland Global Advisors LLC boosted its holdings in shares of iShares Genomics Immunology and Healthcare ETF by 0.7% during the 3rd quarter. Portland Global Advisors LLC now owns 103,007 shares of the company’s stock worth $2,432,000 after buying an additional 684 shares during the period.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.